Tranexamic Acid (TXA)

Tranexamic Acid

The CRASH-2 2 (Clinical Randomisation of an Anti-fibrinolytic in Significant Haemorrhage 2) study involved the randomisation of over 20,000 patients with, or at risk of significant haemorrhage in 40 countries. The study demonstrated a 32% reduction in death due to haemorrhage, when tranexamic acid is administered within 1 h of injury. The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients, and should be considered for use in practice.

Following the publication of the study, the Trust has been working with Professor Stuart Logan, Director of the Peninsula National Institute of Health Research's Collaboration for Leadership in Applied Health Research and Care to implement the intervention across the South West.

For further information please contact Adrian South, Deputy Director of Clinical Care at adrian.south@swast.nhs.uk

Local Resources

Published Evidence

TXA image

Email this page Print page

News

HAVE YOUR SAY AND BECOME A GOVERNOR TODAY
People across the south west wanting to help shape the future of their local ambulance service have the rare opportunity to put themselves forward for the role of Governor. The Trust has over 14000 public and 4000 staff members and it is the membership from the respective constituencies who will vote for a governor to represent them, take forward their views and questions to the Trust’s Board of Directors and engage directly with them.
04/01/2017

Rounded corners
Rounded corners
 
© South Western Ambulance Service NHS Foundation Trust 2017 Design by Precedent | Powered by Sitekit